Pharma Conversations Podcast

In this episode, Charlie Maxwell of Orion GXP Consulting, breaks down what non‑EU pharma and biotech companies need to get right when launching in Europe, from choosing the right HQ location and operating model to deciding between building infrastructure and outsourcing to CDMOs, 3PLs and contract QPs. Charley explains why Europe is not one homogeneous market, how to avoid “tanking your pricing fl...

In this episode, Martin Lush of Martin Lush Consulting, breaks down how pharma organizations can safely and effectively adopt AI without sacrificing GMP, quality, or critical thinking. He explains the four types of AI mindsets in pharma, why “AI knows nothing,” and how overreliance and poor foundational knowledge create real risk. Martin also shares practical examples of prompt engineering, govern...

In this episode Craig Jacobs, Quality Culture Momentum Specialist of Affirm8 Quality Consultancy, unpacks what “quality culture” truly means in life sciences organizations. He explains that real quality shows up when no one is watching on the night shift, in audits, and in everyday process execution. Craig introduces his “4 Ps” model as a way to both understand and measure quality culture over tim...

In this episode, tech transfer expert and lecturer Joe Brady explains why most projects are “already late on day one” and unpacks the real causes of delay across the product lifecycle, from stability studies and PPQ batches to warehouses, materials, and analytical methods. He contrasts innovator to innovator with innovator to CMO transfers, shares hard‑won lessons on auditing, scaling legacy produ...

In this episode of Pharma Conversations, we sit down with Melanie Adams, Associate Director, Knowledge Management at MSD, to unpack what knowledge management really is and how it can be embedded into everyday ways of working. Melanie shares practical strategies for capturing tacit knowledge (including the ROCK tool), accelerating speed to competency, and supporting regulatory readiness. Melanie al...

In this episode, Jim Polarine from STERIS breaks down how Annex 1 is reshaping contamination control strategy world wide covering CCS design, risk‑based decision making, residue management, gowning, environmental monitoring, and material transfer pitfalls like cart wheels. He contrasts Europe and the US, explores the challenges of ageing facilities and new technologies. Contact us at: pharmaconver...

In this episode of Pharma Conversations, Laura Brennan Director of Technical Consulting at Ecolab breaks down the science and regulation behind disinfectant rotation in pharma cleanrooms, from the EU GMP Annex 1 and the FDA expectations to what actually works in practice. She shares new multi-site data on rotation strategies, how to use risk-based EM trends, when to escalate to VHP, and why hands-...

In this episode, Rory Mullen, Head of Biopharma and Food at IDA Ireland, discusses how Ireland has evolved into a leading hub for pharmaceutical and biopharmaceutical manufacturing. He explores where the strongest growth is occurring from biologics and ADCs to GLP-1 weight-loss treatments and explains why global companies continue to invest in high-value operations in Ireland. He also highlights t...

In this episode of Pharma Conversations Podcast, Kevin O’Donnell (HPRA) explains how QRM needs to move beyond tick‑box exercises to become truly knowledge‑driven and evidence‑based. He walks through the main changes in ICH Q9(R1) and what regulators expect from companies in practice. We discuss culture, misuse of RPNs and the idea of a “living” QRM system under continuous improvement. Kevin also s...

In this episode of Pharma Conversations, we’re joined by Patrick Nieuwenhuizen, a global leader in pharmaceutical quality, compliance, and sterility assurance with more than 30 years of experience across sterile manufacturing, biologics, and advanced therapies. Together, we explore the realities of unannounced FDA inspections, the shift toward permanent inspection readiness, and the cultural, oper...

In this episode of Pharma Conversations, we’re joined by Kevin O’Donnell, Market Compliance Manager and Senior GMP Inspector at the HPRA, to discuss what good inspection readiness looks like from a regulator’s perspective. Kevin shares common inspection gaps, how organisations can build continuous readiness, and insights on data integrity, people preparedness, and outsourced activities. He also re...

Matt Moran breaks down the challenges shaping the pharmaceutical industry from supply‑chain fragility and increasing regulatory complexity to the urgent need for sustainability and skilled talent. He highlights why the industry must modernise manufacturing, embrace digitalisation, and build greater resilience to stay competitive in a rapidly shifting global landscape. Matt is a prominent Irish bio...